Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Boehringer Ingelheim and Zealand Pharma are presenting full Phase III SYNCHRONIZE-1 data on survodutide, their glucagon/GLP-1 dual agonist: 16.6% average weight loss at 76 weeks versus 3.2% on placebo
GLP-1 medications work by mimicking the action of the natural hormone GLP-1
A: Ongoing clinical trials and research are evaluating the potential benefits of Retatrutide regarding metabolic health, weight management, and related biological pathways
It is important to consult a doctor before starting treatment, especially for individuals with underlying medical conditions
US$ 29.43
US$ 22.79
US$ 24.06
US$ 26.04
